Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, July 1999, p. 558-566, Vol. 6, No. 4
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Identification of Bartonella-Specific
Immunodominant Antigens Recognized by the Feline Humoral Immune
System
R. L.
Freeland,1
D. T.
Scholl,2
K. R.
Rohde,1
L. J.
Shelton,1 and
K.
L.
O'Reilly1,*
Department of Veterinary Microbiology and
Parasitology1 and Department of
Epidemiology and Community Health,2 School of
Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana
70803
Received 2 September 1998/Returned for modification 14 December
1998/Accepted 2 March 1999
 |
ABSTRACT |
The seroreactivities of both naturally and experimentally infected
cats to Bartonella henselae was examined. Serum samples collected weekly from nine cats experimentally infected with B. henselae LSU16 were tested by enzyme-linked immunosorbent assay (ELISA) and Western blot analysis. The magnitude and isotype of the
antibody response were investigated by ELISA. Western blot analysis
allowed the identification of at least 24 Bartonella-specific antigens recognized by the cats during
infection. Antibody titers to specific antigens, as determined by
Western blot analysis, ranged from 10 to 640 and varied among the
different antibody-antigen interactions. Absorption of sera from an
experimentally infected cat, using whole cells and cell lysates of
various Bartonella species and other bacteria that commonly
colonize cats, supported the identification of those
Bartonella-specific antigens recognized by the
experimentally infected cats. Furthermore, a number of possible
species- and type-specific antigens were identified. Finally, sera
obtained from cats at local animal shelters were screened for the
presence of antibodies directed against the
Bartonella-specific bands identified in the experimentally
infected cats. A number of Bartonella-specific antigens
have been identified to which strong antibody responses are generated
in both experimentally and naturally infected cats, some of which may
be useful in diagnosing species- and/or type-specific infections. In
addition, the results from these experiments will lead to the
development of monoclonal antibodies targeted against those genus-,
species-, and type-specific antigens.
 |
INTRODUCTION |
Bartonella henselae is
the causative agent of human cat scratch disease (CSD) (2, 13, 31,
35) and has been associated with bacillary angiomatosis,
bacillary peliosis, recurrent bacteremia (26), and
endocarditis (14). Epidemiological evidence indicates that
cats serve as vectors for the transmission of B. henselae to
people (27, 40, 42, 43). The cat flea
(Ctenocephalides felis) may also be involved in
transmission of this organism; B. henselae was found in
fleas from an infected cat (26), and it was reported that
fleas (12) and flea feces (19) transferred from
B. henselae-bacteremic cats to specific-pathogen-free cats were capable of transferring the infection. Although cats are the
natural reservoir for B. henselae, they appear to be
asymptomatic even during bacteremic episodes (29, 35). There
is, however, recent evidence to indicate that experimentally infected
cats do present with mild clinical signs, such as fever, anorexia, lethargy, and peripheral lymphadenopathy (1, 22), which
dissipate within a short time. Naturally infected cats may develop
similar clinical signs, but these signs may not be noticed by cat owners.
A strong humoral response to infection with B. henselae has
been seen; whether this immune response is protective against future
infection is debated (12, 20, 36, 37). Furthermore, some
cats with B. henselae bacteremia have high levels of
circulating antibodies, and thus the role of the humoral immune
response in Bartonella infections is not clear
(12). Seroprevalence studies suggest that 3.7 to 65.4% of
cats within the United States are positive for antibodies to B. henselae (9, 10, 25). Serologically positive cats are
often also bacteremic (7, 11, 29). The mechanism by which
this organism is able to survive and replicate within the cat and not
cause overt symptoms is unclear. Similarly, the immunological response
of the cat to this pathogen is not understood.
At this time, pet cats are not routinely screened for
Bartonella infections; screening, however, could be of
particular benefit to those owners who are immunocompromised. The most
widely used serodiagnostic tool for Bartonella infections in
cats are immunofluorescence assays (IFA) (35). The IFA,
however, although specific and sensitive, has a number of drawbacks.
This assay lends itself poorly to large numbers of samples and is
time-consuming and costly. Furthermore, quantitation of IFA requires
that titrations be performed, which increases the cost of the test.
More recently enzyme-linked immunoabsorbent assays (ELISAs) have become
available for diagnosis of Bartonella infections in humans
(30) and in cats (21). While the ELISA is similar
to the IFA in regard to reported sensitivity (86.2 versus 88%) and
specificity (95.9 versus 94%) (21, 36), use of an ELISA has
some inherent advantages. For instance, these assays are particularly
useful because large numbers of samples can be screened at one time,
and the tests are relatively inexpensive.
If the risk of contracting CSD from a pet cat is to be reduced, a
better understanding of the history of the feline Bartonella infection must be obtained. This understanding will further aid in the
improvement of diagnostic tools used in screening for
Bartonella infections. The purpose of this study was to
define the feline humoral immunological response to infection with
Bartonella species. The hypothesis of this research was that
characterization of the feline humoral immune response to infection
with B. henselae will lead to the identification of possible
genus-, species-, and type-specific antigens recognized by the cat's
immune system. These antigens could serve as targets for the generation
of monoclonal antibodies that could be used to improve the
sensitivities and specificities of currently available serodiagnostic tools.
The objectives of this research were (i) to utilize an ELISA to
quantify the magnitude of antibody responses in nine cats experimentally infected with B. henselae LSU16 and to
examine the isotype of these responses; (ii) to perform Western blot
analysis on both unabsorbed and absorbed sera from experimentally
infected cats in order to identify immunodominant proteins recognized
by these cats and to identify those antigens which are possibly
Bartonella genus, species, and type specific; and (iii) to
examine, by Western blot analysis, sera obtained from cats at local
animal shelters for seroreactivity to B. henselae
species-specific antigens and to compare the reactivity patterns of
naturally infected cats to those of the experimentally infected cats.
These results will assist in the identification of those antigens that
would be the most valid targets in the development of
Bartonella-specific diagnostic screening tests and in
determining the usefulness of Western blot analysis as a confirmatory test.
 |
MATERIALS AND METHODS |
Bacteria and culture conditions.
B. henselae Houston-1
(ATCC 49882), Bartonella quintana (ATCC VR-358), and
Bartonella clarridgeiae (ATCC 700095) were obtained from the
American Type Culture Collection (Rockville, Md.). B. henselae LSU16 was isolated at Louisiana State University from a
naturally infected cat. B. quintana and B. henselae Houston-1 and LSU16 were grown on chocolate agar under
5% CO2 at 37°C. B. clarridgeiae was grown on
rabbit blood agar at 35°C under 5% CO2. The bacteria
were scraped from the plates after 5 to 8 days of culture, suspended in
heart infusion broth with 25% glycerol, and stored at
70°C until
they were used. Bordetella bronchiseptica, Pasteurella
multocida, and Escherichia coli were cultivated in Luria-Bertani (39) broth at 37°C for 24 h.
Cats.
Six 12- to 16-week-old kittens (cats 37, 40, 58, 39, 50, and 54) were obtained from animal shelters and underwent
conditioning at the Division of Laboratory Animal Medicine, which
included vaccination and treatment for internal and external parasites. Three additional cats (cats 182, 184, and 223) were obtained from Harlan-Sprague-Dawley, Inc. (Indianapolis, Ind.). At the commencement of the study all nine cats were 6 to 8 months old and negative for
B. henselae by culture and serology. The cats were
maintained at the Division of Laboratory Animal Medicine, Louisiana
State University. All cats were allowed water and food ad libitum and were housed in individual cages according to the policies outlined in
the National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
Sera for the Bartonella seroprevalence study were obtained
from cats at animal shelters in East Baton Rouge, West Baton Rouge, Plaquemine, and Lafayette parishes from May through August 1996.
Experimental infection.
All cats were sedated with Telazol
(Tiletamine HCL and Zolazepam HCL [Fort Dodge Animal Health, Fort
Dodge, Iowa]; 7 mg/kg) prior to venous puncture and experimental
infection. Nine cats were infected intradermally with 5 × 107 CFU of B. henselae LSU16 in
phosphate-buffered saline (1.9 mM NaH2PO4, 8.1 mM Na2HPO4 [pH 7.2], 154 mM NaCl). All cats
were monitored on a daily basis for fever, lymphadenopathy, malaise, anorexia, and any abnormal behavior. Blood was collected by jugular vein puncture every week for 12 weeks (cats 182, 184, and 223), 16 weeks (cats 39, 50, and 54), and 26 weeks (cats 37, 40, and 58) and
cultured for bacterial growth. Serum samples were analyzed by ELISA and
Western blot analysis.
Blood culture.
Blood for culture was collected in 1.5-ml
pediatric lysis-centrifugation isolator tubes (Wampole Laboratories,
Cranbury, N.J.). A 10-µl aliquot of blood was removed from the
isolator tube and 10-fold serially diluted. The dilutions were then
inoculated onto chocolate agar plates. The plates were incubated for 1 to 2 weeks at 37°C under 5% CO2 and checked regularly
for bacterial growth. The number of colonies observed was recorded as
the number of CFU per milliliter of blood. Isolates were periodically
examined microscopically with a Gram stain.
ELISA.
B. henselae Houston-1 was incubated in 50%
(vol/vol) methanol for 4 days to kill the bacteria. The killed bacteria
were lyophilized, resuspended at 1 mg (dry weight) per ml, and treated
with 1% (wt/vol) sodium dodecyl sulfate (SDS). The bacterial
suspension was diluted to 1 µg/ml in sodium carbonate buffer (0.1 M
Na2CO3, 0.1 M NaHCO3, pH 9.6) and
applied to polystyrene Immulon-4 96-well plates (100 µl/well; 1 µg
of protein and 0.001% [wt/vol] SDS per 100 µl). The plates were
incubated overnight at room temperature and then washed five times with
ELISA wash buffer (50 mM Tris, 1 M EDTA, 250 mM NaCl [pH 7.4], and
0.05% [vol/vol] Tween 20). Feline serum samples and positive and
negative controls were diluted 1:200 in ELISA sample buffer (50 mM
Tris, 1 M EDTA, 250 mM NaCl, pH 7.4), and 100 µl was added to the
plates in triplicate. The plates were incubated for 30 min at room
temperature and then washed five times with ELISA wash buffer. One
hundred microliters of a 1:12,800 dilution of peroxidase-conjugated,
affinity-purified goat anti-cat immunoglobulin G (IgG) (Fc fragment;
Bethyl Laboratories, Inc., Montgomery, Tex.) was used for IgG testing.
One hundred microliters of a 1:6,500 dilution of peroxidase-conjugated,
affinity-purified goat anti-cat IgM (µ chain specific; Bethyl
Laboratories, Inc.) was used for IgM testing. The conjugate was
incubated in the wells for 30 min, and they were washed as before.
Next, 100 µl of TMB (Kirkegaard & Perry Laboratories, Inc.,
Gaithersburg, Md.) mixed according to the manufacturer's instructions
was added to the wells and incubated for 10 min, and the incubation was
stopped by addition of 100 µl of 1 M H2SO4.
The plates were read at 410 nm with an ELISA plate reader (Dynatech
Laboratories, Inc., Chantilly, Va.). The optical densities (OD) of the
triplicate wells were averaged in order to obtain an average OD for
each test serum.
Western blot analysis.
Bartonella species cultured as
described above were adjusted to a final OD at 600 nm of 1, and a
bacterial lysate for each species was prepared. The cells were
subjected to centrifugation at 12,000 × g for 10 min,
and then the pelleted cells were resuspended in a half volume of sample
buffer (62.5 mM Tris, 10% [vol/vol] glycerol, 5.0% [vol/vol]
2-mercaptoethanol, 2.3% [wt/vol] SDS), vortexed for 3 min, and
boiled for 10 min. Western blot analysis was performed with
modifications as described for other bacteria (38). Briefly,
75 µl of prepared lysate were electrophoresed on a 12% (wt/vol)
polyacrylamide two-well preparation minigel (Bio-Rad Laboratories,
Richmond, Calif.) at 100 V for 60 to 75 min. Electrophoretically
separated antigens were then transferred to pure nitrocellulose protein
transfer membrane (Schleicher & Schuell, Keene, N.H.) at 100 V for 90 min with an electrophoretic transfer cell (Mini-Trans-Blot; Bio-Rad
Laboratories). The blotted membranes were blocked overnight with 10%
(wt/vol) nonfat dry milk in NET (150 mM NaCl, 1.0 M EDTA, 50 mM Tris,
pH 7.4) (milk-NET) and washed in NET with 0.05% (vol/vol) Tween 20 (NET-T) for 20 min. Feline sera diluted 1:10 in milk-NET were applied
to the blots with a 28-chamber miniblotter (Miniblotter 28; Immunetics, Cambridge, Mass.) and incubated at room temperature for 1 h. The blots were then washed with NET-T and incubated with
peroxidase-conjugated, affinity-purified F(ab') fragment goat anti-cat
IgG (H + L) (Jackson Immunoresearch Inc., Avondale, Pa.) diluted
at 1:5,000 in milk-NET for 1 h. Antibody-bound conjugate was
detected by enhanced chemiluminescence (ECL Western blot detection
system; Amersham Life Science, Inc., Arlington Heights, Ill.). The
enhanced chemiluminescence reagents were diluted 1:2 in distilled water.
Antibody titers for three cats (cats 58, 39, and 182) were examined by
Western blot analysis. Sera obtained from weeks 0, 4, 8, 12, 16, and 20 were each diluted 1:10, 1:40, 1:160, 1:640, 1:2,560, and 1:10,240 with
milk-NET. Upon dilution, the serum samples were processed in the manner
described above.
Absorptions.
Cells from B. henselae Houston-1 and
LSU16, B. clarridgeiae, and B. quintana were
scraped from 20 to 30 chocolate agar plates, subjected to
centrifugation at 15,000 × g for 20 min, and
resuspended in lysis buffer (50 mM Tris-HCL [pH 7.5], 50 mM NaCl, 5%
[vol/vol] glycerol, 1 mM phenylmethylsulfonyl fluoride [PMSF; Sigma
Chemical Co., St. Louis, Mo.], and 1% [vol/vol] aprotinin
[Sigma]). One-liter cultures of B. bronchiseptica,
P. multocida, and E. coli TB1 were propagated in
Luria-Bertani broth, subjected to centrifugation at 15,300 × g for 30 min, and resuspended in lysis buffer. Each suspension
was sonicated (Sonic Dismembrator model 300; Fischer Scientific,
Pittsburgh, Pa.) four times for 30 s each time at 30% maximum
power. After sonication, each lysate was subjected to centrifugation at
27,000 × g for 20 min. The supernatant was used as a
cell lysate, and the remaining pellet was used as a whole organism. The
protein concentration was determined for each cell lysate with the
bicinchoninic acid protein detection system (Pierce Chemical Co.,
Rockford, Ill.) and was adjusted to 2.0 mg/ml. Twenty micrograms of
whole organism was resuspended in 500 µl of undiluted feline serum
with 0.5 mM PMSF and incubated overnight on a rocker at room
temperature. The whole-cell-absorbed serum was then subjected to
centrifugation at 27,000 × g for 10 min, and the
supernatant was collected. Two hundred fifty microliters of
whole-cell-absorbed serum was diluted 1:10 with lysis buffer and stored
at
20°C until it was used, and an additional 200 µl of
whole-cell-absorbed serum was used for the cell lysate absorption. Six
hundred microliters of cell lysate was added to 200 µl of whole-cell-absorbed serum. This was incubated on a rocker at room temperature for approximately 5 h; then, 1 ml of cell lysate was added and incubated overnight on a rocker at room temperature. Finally,
200 µl of cell lysate (for a final serum dilution of 1:10) was added
and incubated for 3 h. As a control, unabsorbed serum was treated
in the same manner as the whole-cell- and whole-cell- and cell
lysate-absorbed sera, with the exception that lysis buffer alone, as
opposed to cell lysate, was added at the specified times. Unabsorbed,
whole-cell-absorbed, and whole-cell- and cell lysate-absorbed sera were
examined by Western blot analysis.
 |
RESULTS |
ELISA for the detection of B. henselae-specific
antibodies.
ELISA analysis was performed in order to examine the
magnitude of antibody response elicited in cats experimentally infected with B. henselae LSU16 and to examine the isotype of the
antibody response. B. henselae-specific IgM and IgG
responses, as well as decreasing primary bacteremia with concurrent
increasing IgG levels, were seen in all experimentally infected cats.
The IgG response in these experimentally infected cats did not fall
over time. While the magnitude of the antibody response varied among the cats, a similar pattern, in which peak IgM levels were followed by
a rise in IgG antibodies, was observed. Three types of antibody responses were seen in these cats: one in which a strong peak in IgM
antibodies occurred within 3 to 5 weeks and was closely followed and
surpassed by a strong IgG antibody response (cats 37, 39, 50, and 184);
another in which the IgM peak did not occur until between 6 and 8 weeks
and was lower than that seen in cats 37, 39, 50, and 184 but was
closely followed with a peak in IgG levels (cats 40, 54, and 182); and
finally, an IgM peak that occurred at 3 weeks but was much lower than
that in the other cats with IgM peaks at 3 weeks (cats 58 and 223).
Interestingly, cat 58 underwent a secondary bacteremia that occurred
without an additional peak in IgM levels or a rise in IgG levels as
seen during primary bacteremia. Furthermore, the magnitude of the IgG
response was lower in cat 58 and developed much more slowly than those
in the other cats. Bacteremias lasted for 5 to 7 weeks in cats 37, 40, 50, and 184 and for 9 to 13 weeks in cats 39, 54, 182, and 223; bacteremia was recurrent in cat 58 (Fig.
1).

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 1.
Bacteremias and antibody responses of nine cats
experimentally infected with B. henselae LSU16. The OD
(primary y axis) for IgM ( ) and IgG ( ) were determined
by ELISA. The OD value at each time point are the averages of
triplicate wells. Bacteremia levels ( ); secondary y axis)
are also shown. Bacteremia levels and antibody responses were followed
for 25 weeks postinfection in cats 37 and 40; 24 weeks postinfection in
cat 58; 15 weeks postinfection in cats 39, 50, and 54; and 12 weeks
postinfection in cats 182, 184, and 223.
|
|
Western blot analysis for the identification of immunodominant
antigens recognized by experimentally infected cats.
Serum samples
collected on a weekly basis were examined by Western blot analysis to
identify immunodominant antigens recognized by the experimentally
infected cats and to determine if there was a predominant pattern of
seroreactivity in these cats (Fig. 2). Sera from all nine
experimentally-infected cats exhibited similar patterns of
immunoreactivity, the exception being the kinetics of the appearance of
antibody to some of the Bartonella-specific antigens
recognized by the cats' immune systems (Fig.
3). At least 24 unique antigens that were
recognized by the immune system of each experimentally infected cat
were identified. A representative blot is shown in Fig.
2 (cat 40). A strong response was
elicited to the following antigens: 97.0, 76.0, 69.0, 65.0, 57.0, 54.0, 45.0, 16.9, 13.3, and 11.3 kDa. This response was evident by no later
than four weeks postinfection and was maintained throughout the course
of observation for each cat. A strong response to the 7.0-, 8.0-, 18.0-, 19.0-, 21.7-, and 51.0-kDa antigens was also elicited in each
cat, but antibodies to these antigens were not detected in all cats
until between 6 and 8 weeks postinfection. Antibodies to these antigens
were also maintained throughout the course of observation. Antibody
responses to the 15.0-kDa band were relatively weak in cats 39, 54, 182, and 223. Responses to the 28.2-kDa band were also weak
in all cats examined. Immune responses to the 15.0-, 28.2-, 30.0-, 33.7-, 36.0-, 48.0-, 60.5-, and 81.0-kDa antigens were
weak, and they waxed and waned throughout the course of
infection.

View larger version (99K):
[in this window]
[in a new window]
|
FIG. 2.
Representative immunoblot from the analysis of
antigen-specific seroreactivity in an experimentally infected cat (cat
40). B. henselae LSU16 antigen preparations were
electrophoretically separated on 12% polyacrylamide gels, transferred
to nitrocellulose, and reacted with 1:10 dilutions of cat sera from
each week postinfection. The twenty-four Bartonella-specific
antigens identified are indicated on the right (-); the approximate
molecular masses of those antigens are (from top to bottom) 97.0, 81.0, 76.0, 69.0, 60.5, 57.0, 54.0, 51.0, 48.0, 45.0, 36.0, 33.3, 30.0, 28.7, 21.7, 19.0, 18.0, 16.9, 15.0, 13.3, 11.3, 8.0, and 7.0 kDa. Molecular
mass markers (in kilodaltons) are shown on the left. The top panel is a
plot of the log 10 CFU/ml of blood determined at each week
postinfection.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 3.
Kinetics of Bartonella-specific antibody
appearance. Serum from each time point postinfection for each of the
nine cats was examined by Western blot analysis for the first
appearance of B. henselae antigen-specific antibodies.
Specifically, the serum was analyzed for seroreactivity to those
molecular mass antigens indicated on the left (in kilodaltons). The
horizontal bars indicate the range of weeks postinfection in which
antibodies to a particular molecular mass antigen first appeared in
each of the nine cats. The gray squares represent the average week
postinfection for each of the nine cats in which antibodies to a
particular antigen were first detectable.
|
|
In order to further examine the magnitude of the feline immune response
to infection with B. henselae, antibody titers to the 97.0-, 76.0-, 69.0-, 65.0-, 45.0-, 16.9-, 15.0-, 13.3-, and 11.3-kDa antigens
were examined by Western blot analysis at 0, 4, 8, 12 (cats 39, 58, and
182), 16 (cats 39 and 58), and 20 (cat 58) weeks postinfection (Table
1). One cat from each pattern of
bacteremia was chosen for titer determination. The peak magnitude of
antibody titers to the 97.0-, 76.0/69.0-, and the 65-kDa antigens reached 640 for cats 39 and 182 and 160 for cat 58. Peak titers of
antibody to the 16.9-, 13.3-, and 11.3-kDa antigens reached 160 for
cats 39 and 182 and 40 for cat 58. Cat 39 had a titer of 160 of
antibody to the 45-kDa protein, while cats 58 and 182 had a peak titer
of 40. The peak titers of antibody to the 15-kDa antigen were low: 40 in cats 58 and 39 and 10 in cat 182. In the cat with recurrent
bacteremia (cat 58), the titers of antibody to the 11.3-, 45.0-, 65.0-, and 76.0/69.0-kDa antigens rose and fell with the bacteremic state of
the cat. Furthermore, the titers of antibody to the 11.3-, 13.3-, 15.0-, 16.9-, and 45.0-kDa antigens waned in cat 58.
Absorptions.
In order to confirm the Bartonella
specificity of those antigens recognized by the experimentally infected
cats, absorptions with whole cells and cell lysates of B. bronchiseptica, P. multocida, and E. coli,
as well as various species of Bartonella, including B. clarridgeiae, B. quintana, B. henselae
Houston-1, and B. henselae LSU16, were performed. Whole-cell
absorption with B. henselae LSU16 removed a majority of the
seroreactivity, indicating that in these experimentally infected cats,
most of the antibodies generated were against external antigens;
absorption with bacterial cell lysate removed the remaining reactive
antibodies (Fig. 4, lanes 1 to 3).
Whole-cell and cell lysate absorption with B. bronchiseptica, P. multocida, and E. coli
did not appear to have any effect on the Western blot antibody-antigen
profile (Fig. 4, lanes 13 to 15). These results suggest that most of
the seroreactive antigens identified by Western blot analysis are
likely Bartonella-specific, since they do not cross-react
with the other bacteria that commonly colonize cats. Absorptions
performed with other species of Bartonella that are known to
be cross-reactive to some extent support these results. B. henselae Houston-1 absorption (Fig. 4, lanes 4 to 6) and B. quintana absorption (Fig. 4, lanes 10 to 12) presented with
antibody profiles similar to that seen with B. henselae
LSU16 with the exception of three antibody-antigen interactions;
B. henselae Houston-1 and B. quintana absorption
did not remove antibodies to the 76.0-, 69.0-, and 65.0-kDa antigens.
These antibodies were also not removed by absorption with B. clarridgeiae (Fig. 4, lanes 7 to 9). Although absorption with
B. clarridgeiae did remove most seroreactivity to the 13.3- and 21.7-kDa antigens, B. clarridgeiae absorption had
little effect on the overall antibody-antigen profile.

View larger version (137K):
[in this window]
[in a new window]
|
FIG. 4.
Immunoabsorption. Cat serum (cat 40) that was previously
absorbed with whole cells (W) and cell lysates (C) of B. henselae LSU16 (lanes 2 and 3), B. henselae Houston-1
(lanes 5 and 6), B. clarridgeiae (lanes 8 and 9), B. quintana (lanes 11 and 12), or B. bronchiseptica,
P. multocida, and E. coli (lanes 14 and 15)
is shown. Unabsorbed serum (U) (lanes 1, 4, 7, 10, and 13) from
cat 40 (B. henselae LSU16 infected) was treated in the same
manner as the absorbed sera. The sera were allowed to react with
B. henselae LSU16 antigen. Bartonella-specific
antigens which were focused upon in this experiment are indicated on
the left (in kilodaltons). Molecular mass markers are shown on the
right (in kilodaltons).
|
|
Bartonella antigen-specific seroreactivity in cats from
local animal shelters.
Sera from 601 cats at local animal shelters
were screened for B. henselae Houston-1 seroreactivity
by Western blot analysis. These blots were examined for the
predominance of those Bartonella immunoreactive antigens
recognized by the experimentally infected cats (Fig.
5). Slight variations from blot to blot
required that those bands which separated as doublets or triplets be
considered as one band. Thus, all sera were examined for reactivity to
16 different proteins with the following molecular masses: 7.0, 8.0, 11.3, 13.3, 15.0, 16.9/18.0, 19.0, 21.7, 28.2, 30.0/36.0, 45.0, 48.0, 51.0/57.0, 60.5/65.0, 69.0/81.0, and 97.0 kDa (Table
2). Reactivity was observed most often
with the 11.3-, 13.3-, 16.9/18.0-, 51.0-/57.0-, 60.5/65.0-,
69.0-/81.0-, and 97.0-kDa antigens. There were 279 different banding
patterns observed, most representing one or two animals; however, 21 patterns which were each found in at least four cats accounted for 43%
of the cats. Sera from 72 cats were reactive with all 16 bands. Forty
cats showed no reactivity to the 16 bands. The most common patterns of
Western blot reactivity are shown in Table
3.

View larger version (133K):
[in this window]
[in a new window]
|
FIG. 5.
Representative immunoblot used in the determination of
the prevalence in 601 cats of Bartonella-specific antibodies
to B. henselae Houston-1 antigen. Sera which reacted to two
of the six molecular mass bands indicated on the right (in kilodaltons)
were considered seropositive (+) for Bartonella-specific
antibodies. Whether a cat was considered seropositive or seronegative
( ) is shown at the top. The sera were also examined for antibodies to
the following Bartonella-specific bands: 19.0, 21.7, 28.7, 30.0 to 36.0, 45.0, 48.0, 51.0 to 57.0, 60.5/65.0, 69.0 to 81.0, and
97.0 kDa.
|
|
The goal of this experiment was to compare the patterns of reactivity
seen in the naturally infected cats with that seen in the
experimentally infected cats. Because the cats from the animal shelters
could have been at any week postinfection when serum was collected and
because they could have been infected with one or more species or types
of Bartonella, and considering the kinetics of antibody
appearance and antibody persistence in the experimentally infected
cats, six antigens were chosen for use in defining a positive cat: 7.0, 8.0, 11.3, 13.3, 15.0, and 16.9/18.0 kDa. Further, to include the
detection of early infections, the requisite that the serum only needed
to react with two of the six molecular mass antigens was established.
Therefore, in this study, a cat was considered
Bartonella-seropositive if it reacted with two of the following six antigens: 7.0, 8.0, 11.3, 13.3, 15.0, and 16.9/18.0 kDa.
Using the above definition, the prevalence of Bartonella
seroreactivity in this population of cats from the local animal
shelters was determined to be 80% (482 of 601). As would be expected,
the naturally infected cats had a wider variability of banding patterns than did the experimentally infected cats. More variable patterns were
seen in the positive cats than in the negative cats (Table 3). The 16 most common positive patterns represent 32.8% of all the cats (197 of
601) and 40.9% (197 of 482) of the positive cats. The five most common
negative patterns represent 10.5% of all the cats (63 of 601) and
53.9% (63 of 119) of the negative cats. The six defining bands are
absent (0 of 63) in the five most common negative patterns. Table
4 summarizes the most common banding patterns with the selected antigens. There were 234 different banding
patterns observed among the 482 seropositive cats, most representing
one or two animals; however, 13 patterns which were each found in at
least five cats accounted for 92.7% (447 of 482) of the positive cats.
There were 45 different banding patterns observed among the 119 seronegative cats, with the 4 most common negative patterns accounting
for 94.1% (112 of 119) of all the negative cats. Thirty-eight percent
(182 of 482) of the positive cats had antibodies to all six bands, and
83% (400 of 482) of the positive cats had antibodies to the 11.3-, 13.3-, and 16.9/18.0-kDa bands.
 |
DISCUSSION |
Immunofluorescent-antibody tests are currently the most widely
used serological tests for the diagnosis of CSD in humans. Regnery et
al. (35) and Zangwill et al. (44) report an 88% sensitivity and a 94% specificity for the IFA. ELISAs, which are inherently less subjective, less expensive, and less
time-consuming than the IFA, are also being developed.
Litwin et al. (30) reported on an enzyme immunoassay (EIA)
to detect IgM and IgG antibodies to B. henselae based on an
outer membrane preparation of B. henselae; the sensitivity
and specificity of this test were indicated to be 94.1 and 99.2%,
respectively, for IgM and 86.2 and 95.9%, respectively, for IgG.
Western blot analysis of sera from patients with CSD has also been
performed in order to identify critical antigens involved in eliciting
an immune response in humans. A 17-kDa antigen has been identified
that, when used as an EIA test antigen for Bartonella
seroreactivity, showed an agreement of 92% with IFA-positive serum
samples and 88% with IFA-negative serum samples (3). The
outer membrane preparation used by Litwin et al. (30)
consisted of several antigens that reacted with sera from patients with CSD: 209-, 208.5-, 208-, 116-, 80.0-, 30.0-, 23.0-, 10.0-, and 8.0-kDa
bands, along with a cluster of proteins with molecular masses ranging
from 35.0 to 49.0 kDa. A strong correlation between reactivity to the
8.0-kDa band and a positive result by IFA and EIA was reported
(30). The approximate molecular masses of other Bartonella-immunoreactive antigens that have been reported
include 97.0-, 69.0-, 45.0-, and 23.0-kDa (41) and 48.5-kDa
(32). Identification of these immunodominant antigens is
leading to the development of monoclonal antibodies targeted to those
specific antigens. For instance, it has recently been reported that
B. henselae species-specific monoclonal antibodies to a
40.0- and a 30.0-kDa antigen have been generated (33).
Identification of immunodominant antigens and the generation of
monoclonal antibodies to these antigens should lead to a greater
understanding of the human immune response to CSD and to improved
diagnostic tests.
While a great deal of progress has been made in studying the human
humoral immune response to CSD, less is known about the feline humoral
immune response to Bartonella infections. Furthermore, the
role of antibody in the pathogenesis of Bartonella
infections in both humans and cats has not been determined. Feline
serological surveys to date have been done by IFA (10, 11, 23, 25, 35). EIAs with outer membrane preparations for detecting serum antibodies in experimentally infected cats have also been utilized (21). Currently, there are no reports on Western blot
analysis of feline sera for the purpose of screening for
Bartonella-reactive antibodies. Thus, the aims of this study
were (i) to examine the feline humoral immune response to infection
with B. henselae by ELISA; (ii) to identify, using Western
blot analysis and absorption assays, those antigens which are
recognized by the cat's immune system and possible species- and
type-specific immunoreactive antigens; and (iii) to determine the
seroprevalence of Bartonella in cats from local animal
shelters based on the presence of antibodies to those
Bartonella-specific antigens identified in step 2 and to
examine the sensitivities and specificities of individual bands against
an internal standard.
Using nine cats experimentally infected with B. henselae, we
were able to follow the development of the feline humoral immune response to B. henselae. All nine cats developed IgM and IgG
responses that, although variable in magnitude between cats, were
characterized by a peak in IgM levels followed by a rise in IgG levels.
In each cat, primary bacteremia decreased as IgG levels increased.
Decreasing bacteremia with increasing IgG levels has been reported in
other studies (5). Three patterns of bacteremia were seen in
the nine experimentally infected cats: one pattern in which cats became abacteremic by week 7 (cats 37, 40, 50, and 184), a second pattern in
which cats became abacteremic between weeks 9 and 13 (cats 39, 54, 182, and 223), and a third pattern in which the cat underwent a secondary
bacteremia (cat 58). Interestingly, in the one cat (58) that underwent
a secondary bacteremia the IgM levels remained low throughout the
course of infection, the IgG response developed much more slowly than
those in the other eight cats, and virtually no change in the IgM
levels was seen from the end of the primary bacteremia to the
commencement of the secondary bacteremia. The apparent abacteremic
state of cat 37 in week 4, cat 54 in week 8, and cat 58 in weeks 7 to 9 may represent bacteremias below the level of detection (<33 CFU/ml of
blood) in our assay rather than true abacteremia.
Western blot analysis of the sera from the experimentally infected cats
identified at least 24 Bartonella-specific bands that were
immunogenic in all nine cats. We observed detectable levels of
antibodies to some of these antigens (11.3-, 13.3-, 16.0/18.0-, 45.0-, 65.0-, 69.0-, and 76.0-kDa bands) by 3 weeks postinfection, while
others did not appear until 4 to 8 weeks postinfection (7.0-, 8.0-, 19.0-, 21.7-, 30.0-, 33.3-, 36.0-, 48.0-, 51.0-, 54.0-, 57.0-, 60.5-,
81.0-, and 97.0-kDa bands). The different kinetics for antigen-specific
antibody responses seen with each cat suggest that the antigenicity of
B. henselae LSU16 is dependent upon the individual cat's
immune system.
While it is difficult to compare bands of reactivity in Western blots
from one study to another because of variations in protein preparations
and electrophoretic conditions, many of the same molecular mass
antigens reported in this study have been found in other studies with
human sera. However, it has not been determined whether any of the
antigens identified in this study are equivalent to those identified in
the human serum studies. Those antigens identified in this study that
have not been found in other Western blotting studies may reflect
differences between the immune responses of humans and cats. In
addition, these differences could be a result of antigenic variability
among B. henselae strains.
The titer in serum from one cat with each pattern of bacteremia was
determined in order to examine the magnitude of the antibody responses
to particular antigens and to determine if there was any relationship
between the titer of the antibody response and the bacteremic state of
the cat. Cat 58, which underwent a secondary bacteremia, generated an
antibody titer lower than that generated by cats 39 and 182 to all of
the bands examined. Furthermore, the titer of the antibody response
generated by cat 182 increased much more slowly than that generated by
cat 39, even though the levels of bacteremia were approximately the
same throughout the course of infection (except that the bacteremia in
cat 182 persisted for 3 weeks longer than that in cat 39). Thus, it
appears that the duration of bacteremia may be related to the magnitude
of the antibody response (titer) generated. Chomel et al.
(11) reported a similar association, in which titers were
higher in bacteremic cats than in nonbacteremic cats. Together, these
results may suggest a role for antibodies in the clearance of B. henselae. It has not been determined if antibodies are protective;
however, passive-transfer studies could be useful in addressing these
questions. Although the titer numbers for the low-molecular-mass bands
are generally lower than those for the higher-molecular-mass bands, this may not truly represent a difference in immunoreactivity. The
difference could be a result of more epitopes being available on
higher-molecular-mass antigens for interaction with specific antibodies. These results warrant further investigation.
DNA hybridization studies comparing the interrelatedness of various
species of Bartonella indicate that B. henselae
Houston-1 and B. quintana are 71% related (8)
while B. henselae Houston-1 and B. clarridgeiae
are only 47% related (28). DNA hybridization studies have
not been performed for B. henselae LSU16. Comparative seroreactive studies of cats, rabbits, and humans have been
described in the literature (4, 19, 34). It has been shown
by IFA that absorption of cat serum with B. henselae is able to distinguish species-specific reactivity to
B. henselae from cross-reactivity to B. quintana antigen (4). Immunoelectrophoretic
studies with rabbit sera and antigen preparations of B. henselae and B. quintana indicate that rabbits
produce antibodies to seven unique antigenic proteins when
immunized with B. henselae compared to immunization with
B. quintana (17).
In our study B. henselae Houston-1 absorption and B. quintana absorption of serum from a cat experimentally infected
with B. henselae LSU16 yielded antibody profiles that were
indistinguishable from each other. However, these two absorption
antibody profiles were different from that of the absorption performed
with B. henselae LSU16 in that antibodies to the 76.0-, 69.0-, and 65.0-kDa antigens were not removed. Two variants (type 1 and
type 2) of B. henselae have been identified based on
sequence differences in the 16S rRNA (6). B. henselae LSU16 has not been typed at this time, and it is possible
that B. henselae LSU16 could represent a type 2 variant,
whereas B. henselae Houston-1 has been identified as a
type 1 variant. Alternatively, the difference in absorption antibody
profiles may represent the loss of these immunodominant antigens
through multiple passage of the Houston-1 strain; B. henselae LSU16 is a new isolate that has not been extensively passaged. Cross-reactivity with the 13.3-kDa antigen was found for each
of the Bartonella species examined. While some antibody profiles did not appear to be affected by absorption,
antigen-specific titers could have decreased; this experiment
does not directly address this question.
The high degree of diversity among Bartonella species sheds
some doubt on the sensitivities of various diagnostic procedures. A
prevalence study of B. clarridgeiae based on blood culture
estimates a 16% prevalence in stray cats (24). Considering
the relatively low DNA relatedness and the lack of cross-reactivity
between B. henselae Houston-1 and B. clarridgeiae, it is likely that IFA seroprevalence studies
utilizing a B. henselae antigen preparation would
underestimate the number of cats with antibodies to
Bartonella. Evidence for this supposition is provided in a
study in which a patient with CSD was seronegative for B. henselae, B. quintana, and Bartonella
elizabethae but was seropositive for B. clarridgeiae (28). Furthermore, a number of patients with CSD who
tested negative by IFA for B. henselae Houston-1
were determined to be seropositive for B. henselae Marseille (15). Some studies have indicated
that 60% of patients with CSD test negative in standard IFA (16,
42). Development of a test that includes antigens specific to the
various species and types of Bartonella is critical in
improving the sensitivities of the IFA and other diagnostic tests.
In examining the sera from the 601 cats at local animal shelters for
Bartonella seroreactivity, a number of antigens were identified that could aid in the improvement of Bartonella
serology tests. The Western blotting and titration results indicated
that a strong antibody response to the 13.3-kDa antigen was generated and that the response persisted throughout the course of infection. In
addition, this antigen was present in a high percentage of shelter cats
in association with other bands which appear to be Bartonella specific. Together, these results suggest that
the utilization of this antigen as a test antigen may be beneficial in
improving serological tests. The use of the 11.3- or 16.9/18.0-kDa antigens as test antigens could help to increase the sensitivity of
serological tests; antibodies to these antigens and to the 13.3-kDa
antigen were not detected in the most common negative patterns of
seroreactivity (Table 3). On the other hand, the 76.0-, 69.0-, and
65.0-kDa antigens may be extremely useful in distinguishing between
seroreactivity with B. henselae LSU16 and cross-reactivity
with B. henselae Houston-1. The 97.0-kDa protein may also
serve as a useful test antigen. However, these antigens were not
present in as many animals and thus the number of false negatives with
these antigens may be higher. Grouping of some of the
higher-molecular-mass antigens may have affected the usefulness of each
individual antigen. In the prevalence determination, the higher-molecular-mass antigens were not initially considered because of
the difficulty in determining the molecular mass of each antigen from
gel to gel (due probably to slight variations in protein preparation
and electrophoretic conditions). Future studies utilizing a decreased
percentage of polyacrylamide will result in greater separation of the
higher-molecular-mass antigens. Greater separation of these antigens
should yield a better picture of the immune response to them. In a
situation where a highly specific test is desired, the use of the 21.7- and 28.0-kDa antigens as test antigens would be beneficial. The 7.0-, 8.0-, and 15.0-kDa antigens were used as screen test antigens because,
although these antigens were not detected in as many positive cats, the
antibody responses to the antigens when seen produced a signal that was
easy to detect by Western blot analysis. We would expect that the
sensitivities associated with these antigens will be lower, given that
the antibody responses to the antigens waxed and waned throughout the
course of infection. While these three antigens may not be useful in improving the sensitivities of Bartonella serology tests,
they may be used to differentiate between an acute infection and a chronic infection. However, this has not been determined and warrants further investigation.
In designing an antibody-based Bartonella screening test, a
number of factors, such as the stage of infection, the degree of
infection, the immunological state and response of the infected individual, and the serotype of the infecting organism, must be considered; all of these factors can influence the results of the test.
An ideal test is one that could handle all the variabilities associated
with these factors; however, it is unlikely that a test with only one
antigen could meet this criterion. Based on the results of this study,
a test with some combination of the 11.3-, 13.3-, and 16.9/18.0-kDa
antigens may be prudent.
Absorption assays and Western blot analysis have proven to be useful
tools in identifying a number of Bartonella-specific immunodominant antigens recognized by the feline immune system during
experimental infection with B. henselae LSU16. The
generation and use of multiple monoclonal antibodies against these
antigens will aid in improving the sensitivities and specificities of
various serological diagnostic tests. Additional studies of the feline humoral immune response to infection with Bartonella should
help to identify the roles of these antigens in the immune response. Furthermore, these studies should lead to the advancement of our understanding of the pathogenesis of infections due to this microorganism.
 |
ACKNOWLEDGMENTS |
This work was supported by NIH grant 1 R15 AI39720-01.
We thank Patricia Triche, Leslie Birke, Laura Blanke, Tracy Brown,
David Good, Victor Goss, Malgorzata Mikoloczyk, Katy Parr, Kenny
Ransom, and Jeff Taylor for technical assistance; Melanie Rembert and
Laurie Henderson for their assistance with the cats; and Keith Hughes
for useful discussions.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Veterinary Microbiology and Parasitology, Louisiana State
University-School of Veterinary Medicine, South Stadium Dr., Baton
Rouge, LA 70803. Phone: (504) 346-3307. Fax: (504) 346-5715. E-mail: oreilly{at}mail.vetmed.lsu.edu.
 |
REFERENCES |
| 1.
|
Abbott, R. C.,
B. B. Chomel,
R. W. Kasten,
K. A. Floyd-Hawkins,
Y. Kikuchi,
J. E. Koehler, and N. C. Pedersen.
1997.
Experimental and natural infection with Bartonella henselae in domestic cats.
Comp. Immunol. Microbiol. Infect. Dis.
20:41-51[Medline].
|
| 2.
|
Adal, K. A.,
C. J. Cockerell, and W. A. Petri, Jr.
1994.
Cat scratch disease, bacillary angiomatosis, and other infections due to Rochalimaea.
N. Engl. J. Med.
330:1509-1515[Free Full Text].
|
| 3.
|
Anderson, B.,
E. Lu,
D. Jones, and R. Regnery.
1995.
Characterization of a 17-kilodalton antigen of Bartonella henselae reactive with sera from patients with cat scratch disease.
J. Clin. Microbiol.
33:2358-2365[Abstract].
|
| 4.
|
Baneth, G.,
D. L. Kordick,
B. C. Hegarty, and E. B. Breitschwerdt.
1996.
Comparative seroreactivity to Bartonella henselae and Bartonella quintana among cats from Israel and North Carolina.
Vet. Microbiol.
50:95-103[Medline].
|
| 5.
|
Bergmans, A. M.
1996.
Cat scratch disease: studies on diagnosis and identification of reservoirs and vectors. Ph.D. dissertation.
University of Utrecht, Utrecht, The Netherlands.
|
| 6.
|
Bergmans, A. M.,
J. F. Schellekens,
J. D. van Embden, and L. M. Schouls.
1996.
Predominance of two Bartonella henselae variants among cat-scratch disease patients in The Netherlands.
J. Clin. Microbiol.
34:254-260[Abstract].
|
| 7.
|
Breitschwerdt, E. B.,
D. L. Kordick,
D. E. Malarkey,
B. Keene,
T. L. Hadfield, and K. Wilson.
1995.
Endocarditis in a dog due to infection with a novel Bartonella subspecies.
J. Clin. Microbiol.
33:154-160[Abstract].
|
| 8.
|
Brenner, D. J.,
S. P. O'Connor,
H. H. Winkler, and A. G. Steigerwalt.
1993.
Proposals to unify the genera Bartonella and Rochalimaea, with descriptions of Bartonella quintana comb. nov., Bartonella vinsonii comb. nov., Bartonella henselae comb. nov., and Bartonella elizabethae comb. nov., and to remove the family Bartonellaceae from the order Rickettsiales.
Int. J. Syst. Bacteriol.
43:777-786[Abstract/Free Full Text].
|
| 9.
|
Childs, J. E.,
J. G. Olson,
A. Wolf,
N. Cohen,
Y. Fakile,
J. A. Rooney,
F. Bacellar, and R. L. Regnery.
1995.
Prevalence of antibodies to Rochalimaea species (cat-scratch disease agent) in cats.
Vet. Rec.
136:519-520[Medline].
|
| 10.
|
Childs, J. E.,
J. A. Rooney,
J. L. Cooper,
J. G. Olson, and R. L. Regnery.
1994.
Epidemiologic observations on infection with Rochalimaea species among cats living in Baltimore, Md.
J. Am. Vet. Med. Assoc.
204:1775-1778[Medline].
|
| 11.
|
Chomel, B. B.,
R. C. Abbott,
R. W. Kasten,
K. A. Floyd-Hawkins,
P. H. Kass,
C. A. Glaser,
N. C. Pedersen, and J. E. Koehler.
1995.
Bartonella henselae prevalence in domestic cats in California: risk factors and association between bacteremia and antibody titers.
J. Clin. Microbiol.
33:2445-2450[Abstract].
|
| 12.
|
Chomel, B. B.,
R. W. Kasten,
K. Floyd-Hawkins,
B. Chi,
K. Yamamoto,
J. Roberts-Wilson,
A. N. Gurfield,
R. C. Abbott,
N. C. Pedersen, and J. E. Koehler.
1996.
Experimental transmission of Bartonella henselae by the cat flea.
J. Clin. Microbiol.
34:1952-1956[Abstract].
|
| 13.
|
Dolan, M. J.,
M. T. Wong,
R. L. Regnery,
J. H. Jorgensen,
M. Garcia,
J. Peters, and D. Drehner.
1993.
Syndrome of Rochalimaea henselae adenitis suggesting cat scratch disease.
Ann. Intern. Med.
118:331-336[Abstract/Free Full Text].
|
| 14.
|
Drancourt, M.,
R. Birtles,
G. Chaumentin,
F. Vandenesch,
J. Etienne, and D. Raoult.
1996.
New serotype of Bartonella henselae in endocarditis and cat-scratch disease.
Lancet
347:441-443[Medline].
|
| 15.
|
Drancourt, M.,
R. Birtles,
G. Chaumentin,
F. Vandenesch,
J. Etienne, and D. Raoult.
1996.
New serotype of Bartonella henselae in endocarditis and cat-scratch disease.
Lancet
347:441-443. (Erratum, 347:842.
|
| 16.
|
Dupon, M.,
D. L. A. Savin,
P. Brouqui,
M. Drancourt,
D. Raoult,
A. De Mascarel, and J. Y. Lacut.
1996.
Evaluation of serological response to Bartonella henselae, Bartonella quintana, and Afipia felis antigens in 64 patients with suspected cat-scratch disease.
Scand. J. Infect. Dis.
28:361-366[Medline].
|
| 17.
|
Engbaek, K., and C. Koch.
1994.
Antibody response in rabbits infected with Rochalimaea henselae, Rochalimaea quintana, and Afipia felis.
J. Pediatr. Child Health
30:467-469.
|
| 18.
|
Engbaek, K., and C. Koch.
1994.
Immunoelectrophoretic characterization and cross-reactivity of Rochalimaea henselae, Rochalimaea quintana, and Afipia felis.
APMIS
102:931-942[Medline].
|
| 19.
|
Foil, L.,
E. Andress,
R. L. Freeland,
A. F. Roy,
R. Rutledge,
P. C. Triche, and K. L. O'Reilly.
1998.
Experimental infection of domestic cats with Bartonella henselae by inoculation of Ctenocephalides felis (Siphonaptera: Pulicidae) feces.
J. Med. Entomol.
35:625-628[Medline].
|
| 20.
|
Greene, C. E.,
M. McDermott,
P. H. Jameson,
C. L. Atkins, and A. M. Marks.
1996.
Bartonella henselae infection in cats: evaluation during primary infection, treatment, and rechallenge infection.
J. Clin. Microbiol.
34:1682-1685[Abstract].
|
| 21.
|
Guptill, L.,
L. Slater,
C. Wu,
T. Lin,
L. Glickman,
D. Welch,
J. Tobolski, and H. HogenEsch.
1997.
Experimental infection of neonatal specific pathogen free cats with Bartonella henselae, p. 8.
In
Second International Symposium on Feline Immunology.
|
| 22.
|
Guptill, L.,
L. Slater,
C. C. Wu,
T. L. Lin,
L. T. Glickman,
D. F. Welch, and H. HogenEsch.
1997.
Experimental infection of young specific pathogen-free cats with Bartonella henselae.
J. Infect. Dis.
176:206-216[Medline].
|
| 23.
|
Gurfield, A. N.,
H. J. Boulouis,
B. B. Chomel,
R. Heller,
R. W. Kasten,
K. Yamamoto, and Y. Piemont.
1997.
Coinfection with Bartonella clarridgeiae and Bartonella henselae and with different Bartonella henselae strains in domestic cats.
J. Clin. Microbiol.
35:2120-2123[Abstract].
|
| 24.
|
Heller, R.,
M. Artois,
V. Xemar,
D. de Briel,
H. Gehin,
B. Jaulhac,
H. Monteil, and Y. Piemont.
1997.
Prevalence of Bartonella clarridgeiae in stray cats.
J. Clin. Microbiol.
35:1327-1331[Abstract].
|
| 25.
|
Jameson, P.,
C. Greene,
R. Regnery,
M. Dryden,
A. Marks,
J. Brown,
J. Cooper,
B. Glaus, and R. Greene.
1995.
Prevalence of Bartonella henselae antibodies in pet cats throughout regions of North America.
J. Infect. Dis.
172:1145-1149[Medline].
|
| 26.
|
Koehler, J. E.,
C. A. Glaser, and J. W. Tappero.
1994.
Rochalimaea henselae infection. A new zoonosis with the domestic cat as reservoir.
JAMA
271:531-535[Abstract].
|
| 27.
|
Koehler, J. E.,
M. A. Sanchez,
C. S. Garrido,
M. J. Whitfeld,
F. M. Chen,
T. G. Berger,
M. C. Rodriguez-Barradas,
P. E. LeBoit, and J. W. Tappero.
1997.
Molecular epidemiology of Bartonella infections in patients with bacillary angiomatosis-peliosis.
N. Engl. J. Med.
337:1876-1883[Abstract/Free Full Text].
|
| 28.
|
Kordick, D. L.,
E. J. Hilyard,
T. L. Hadfield,
K. H. Wilson,
A. G. Steigerwalt,
D. J. Brenner, and E. B. Breitschwerdt.
1997.
Bartonella clarridgeiae, a newly recognized zoonotic pathogen causing inoculation papules, fever, and lymphadenopathy (cat scratch disease).
J. Clin. Microbiol.
35:1813-1818[Abstract].
|
| 29.
|
Kordick, D. L.,
K. H. Wilson,
B. C. Hegarty,
H. A. Berkoff, and E. B. Breitschwerdt.
1994.
Bartonella (Rochalimaea) bacteremia in three feline populations.
In
Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
| 30.
|
Litwin, C. M.,
T. B. Martins, and H. R. Hill.
1997.
Immunologic response to Bartonella henselae as determined by enzyme immunoassay and Western blot analysis.
Am. J. Clin. Pathol.
108:202-209[Medline].
|
| 31.
|
Margileth, A. M., and G. F. Hayden.
1993.
Cat scratch disease. From feline affection to human infection.
N. Engl. J. Med.
329:8-13[Abstract/Free Full Text].
|
| 32.
|
Maurin, M.,
V. Roux,
A. Stein,
F. Ferrier,
R. Viraben, and D. Raoult.
1994.
Isolation and characterization by immunofluorescence, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, Western blot, restriction fragment length polymorphism-PCR, 16S rRNA gene sequencing, and pulsed-field gel electrophoresis of Rochalimaea quintana from a patient with bacillary angiomatosis.
J. Clin. Microbiol.
32:1166-1171[Abstract/Free Full Text].
|
| 33.
|
McGill, S.,
H. Sjodin-Berglund,
M. Merza, and L. Engstand.
1998.
Novel species-specific murine monoclonal antibodies against Bartonella henselae: diagnostic implications, abstr. 167. In Program and abstracts of the 98th Annual Meeting of the American Society for Microbiology.
American Society for Microbiology, Washington, D.C.
|
| 34.
|
Raoult, D., and B. La Scola.
1996.
Serological cross reactions between Bartonella quintana, Bartonella henselae, and Coxiella burnetii.
J. Clin. Microbiol.
34:2270-2274[Abstract].
|
| 35.
|
Regnery, R. L.,
J. G. Olson,
B. A. Perkins, and W. Bibb.
1992.
Serological response to "Rochalimaea henselae" antigen in suspected cat-scratch disease.
Lancet
339:1443-1445[Medline].
|
| 36.
|
Regnery, R. L.,
J. A. Rooney,
A. M. Johnson,
S. L. Nesby,
P. Manzewitsch,
K. Beaver, and J. G. Olson.
1996.
Experimentally induced Bartonella henselae infections followed by challenge exposure and antimicrobial therapy in cats.
Am. J. Vet. Res.
57:1714-1719[Medline].
|
| 37.
|
Rodriguez-Barradas, M. C.,
J. C. Bandres,
R. J. Hamill,
J. Trial,
J. E. Clarridge,
R. E. Baughn, and R. D. Rossen.
1995.
In vitro evaluation of the role of humoral immunity against Bartonella henselae.
Infect. Immun.
63:2367-2370[Abstract].
|
| 38.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed., p. 18.2-18.88.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 39.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed., p. A.1.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 40.
|
Tappero, J. W.,
J. Mohle-Boetani,
J. E. Koehler,
B. Swaminathan,
T. G. Berger,
P. E. LeBoit,
L. L. Smith,
J. D. Wenger,
R. W. Pinner,
C. A. Kemper, et al.
1993.
The epidemiology of bacillary angiomatosis and bacillary peliosis.
JAMA
269:770-775[Abstract].
|
| 41.
|
Welch, D. F.,
D. M. Hensel,
D. A. Pickett,
V. H. San Joaquin,
A. Robinson, and L. N. Slater.
1993.
Bacteremia due to Rochalimaea henselae in a child: practical identification of isolates in the clinical laboratory.
J. Clin. Microbiol.
31:2381-2386[Abstract/Free Full Text].
|
| 42.
|
Yoshida, H.,
N. Kusaba,
K. Omachi,
N. Miyazaki,
M. Yamawaki,
Y. Tsuji,
K. Nakahara,
M. Sumino,
M. Noudomi,
Y. Shimokawa, and K. Tanikawa.
1996.
Serological study of Bartonella henselae in cat scratch disease in Japan.
Microbiol. Immunol.
40:671-673[Medline].
|
| 43.
|
Zangwill, K. M.,
D. H. Hamilton,
B. A. Perkins,
R. L. Regnery,
B. D. Plikaytis,
J. L. Hadler,
M. L. Cartter, and J. D. Wenger.
1993.
Cat scratch disease in Connecticut. Epidemiology, risk factors, and evaluation of a new diagnostic test.
Vet. Rec.
133:27-28[Medline].
|
| 44.
|
Zangwill, K. M.,
D. H. Hamilton,
B. A. Perkins,
R. L. Regnery,
B. D. Plikaytis,
J. L. Hadler,
M. L. Cartter, and J. D. Wenger.
1993.
Cat scratch disease in Connecticut. Epidemiology, risk factors, and evaluation of a new diagnostic test.
N. Engl. J. Med.
329:8-13.
|
Clinical and Diagnostic Laboratory Immunology, July 1999, p. 558-566, Vol. 6, No. 4
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Gilmore, R. D. Jr., Bellville, T. M., Sviat, S. L., Frace, M.
(2005). The Bartonella vinsonii subsp. arupensis Immunodominant Surface Antigen BrpA Gene, Encoding a 382-Kilodalton Protein Composed of Repetitive Sequences, Is a Member of a Multigene Family Conserved among Bartonella Species. Infect. Immun.
73: 3128-3136
[Abstract]
[Full Text]
-
Litwin, C. M, Johnson, J. M, Martins, T. B
(2004). The Bartonella henselae sucB gene encodes a dihydrolipoamide succinyltransferase protein reactive with sera from patients with cat-scratch disease. J Med Microbiol
53: 1221-1227
[Abstract]
[Full Text]
-
Chenoweth, M. R., Greene, C. E., Krause, D. C., Gherardini, F. C.
(2004). Predominant Outer Membrane Antigens of Bartonella henselae. Infect. Immun.
72: 3097-3105
[Abstract]
[Full Text]
-
Ketring, K. L., Zuckerman, E. E., Hardy, W. D. Jr.
(2004). Bartonella: A New Etiological Agent of Feline Ocular Disease. Journal of the American Animal Hospital Association
40: 6-12
[Full Text]
-
Gilmore, R. D. Jr., Carpio, A. M., Kosoy, M. Y., Gage, K. L.
(2003). Molecular Characterization of the sucB Gene Encoding the Immunogenic Dihydrolipoamide Succinyltransferase Protein of Bartonella vinsonii subsp. berkhoffii and Bartonella quintana. Infect. Immun.
71: 4818-4822
[Abstract]
[Full Text]
-
Houpikian, P., Raoult, D.
(2003). Western Immunoblotting for Bartonella Endocarditis. CVI
10: 95-102
[Abstract]
[Full Text]
-
Yamamoto, K., Chomel, B. B., Kasten, R. W., Hew, C. M., Weber, D. K., Lee, W. I., Droz, S., Koehler, J. E.
(2002). Experimental Infection of Domestic Cats with Bartonella koehlerae and Comparison of Protein and DNA Profiles with Those of Other Bartonella Species Infecting Felines. J. Clin. Microbiol.
40: 466-474
[Abstract]
[Full Text]
-
O'Reilly, K. L., Parr, K. A., Brown, T. P., Tedder-Ferguson, B., Scholl, D. T.
(2001). Passive Antibody to Bartonella henselae Protects against Clinical Disease following Homologous Challenge but Does Not Prevent Bacteremia in Cats. Infect. Immun.
69: 1880-1882
[Abstract]
[Full Text]
-
Liang, Z., Raoult, D.
(2000). Differentiation of Bartonella Species by a Microimmunofluorescence Assay, Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis, and Western Immunoblotting. CVI
7: 617-624
[Abstract]
[Full Text]